Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 85.4%

Gross margin was 85.4% in Q1 FY2026, down 14.6 pp from a year earlier. On a trailing-twelve-month basis it was -153.7%, up 248.0 pp year over year. Over 3 fiscal years it narrowed by 9.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
85.4%+11.5 pp QoQ
Last fiscal yearDec 2025
76.5%-5.8 pp YoY
LTMMar 2026
-153.7%+248.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-14.6 pp——
1 year-5.8 pp——
3 years-9.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
76.5%
Year-over-year change
-5.8pp

Gross Margin vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's LTM Mar 2026 gross margin of -153.7% is the 7th highest of the 8 companies compared; the peer median is 82.6%.
  • Its year-over-year change of +248.0 pp is the 2nd highest of 8, against a peer median of +64.6 pp.
  • Over three fiscal years its change of -9.0 pp compares with a peer median of -6.0 pp.
NTLA Competitors Peer median
Gross Margin for NTLA and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
PGENPrecigen, Inc.LTM Jun 202689.6% +108.3 pp-39.4 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-558.9% -202.1 pp+18649.7 pp
SANASana Biotechnology, Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NTLA) 82.6%+64.6 pp-6.0 pp

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.05M52.12M36.28M57.88M67.67M
Cost of Revenue6.89M7.57M8.98M10.29M15.92M
Gross Profit26.16M44.55M27.3M47.59M51.75M
Gross Margin79.2%85.5%75.3%82.2%76.5%
Research & Development229.81M419.98M435.07M466.31M388.86M
Selling, General & Admin71.1M90.31M116.5M125.83M119.8M
Operating Expenses294.01M502.71M542.59M581.86M492.74M
Depreciation & Amortization6.89M7.57M8.98M10.29M15.92M
EBITDA(261M)(466.61M)(472.22M)(508.74M)(396.77M)
EBITDA Margin-789.6%-895.3%-1301.8%-879.0%-586.3%
Operating Income(267.85M)(458.16M)(515.29M)(534.26M)(440.99M)
Operating Margin-810.4%-879.0%-1420.5%-923.1%-651.7%
Interest Income1.28M8.54M49.83M47.81M29.2M
Interest Expense00000
Other Income / Expenses(42K)(16.02M)34.1M15.24M28.3M
Income Before Tax(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Pre-Tax Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
Income Tax Expense00000
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Net Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
EPS (Basic)(3.78)(6.16)(5.42)(5.25)(3.81)
EPS (Diluted)(3.78)(6.16)(5.42)(5.25)(3.81)
Weighted Avg Shares70.89M76.97M88.77M98.85M108.38M
Weighted Avg Shares (Diluted)70.89M76.97M88.77M98.85M108.38M

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.